FindTrial
Sign In

Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

JNJ-53718678 RSV Pre-Approval Access_Single Patient Access (SPR) for Patients Diagnosed With RSV

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04221412
Enrollment
Unknown
Registered
2020-01-09
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Syncytial Virus

Brief summary

The purpose of this pre-approval access program is to provide treatment to immunocompromised participants with serious/life-threatening diseases or conditions (Respiratory Syncytial Virus \[RSV\] infection) and to collect the safety data to understand the safety profile of JNJ-53718678.

Interventions

DRUGJNJ-53718678

JNJ-53718678 will be administered as directed by treating physician.

Sponsors

Janssen Sciences Ireland UC
Lead SponsorINDUSTRY

Eligibility

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026